These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 32066856

  • 21. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
    Ke L, Xu M, Jiang X, Sun X.
    Med Sci Monit; 2018 Dec 23; 24():9364-9369. PubMed ID: 30580372
    [Abstract] [Full Text] [Related]

  • 22. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ, Illei PB, Lin MT, Ettinger DS, Maleki Z.
    Hum Pathol; 2014 Dec 23; 45(12):2379-87. PubMed ID: 25288236
    [Abstract] [Full Text] [Related]

  • 23. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.
    Cancer; 2012 Feb 01; 118(3):729-39. PubMed ID: 21720997
    [Abstract] [Full Text] [Related]

  • 24. Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma.
    DeMaio A, Clarke JM, Dash R, Sebastian S, Wahidi MM, Shofer SL, Cheng GZ, Li X, Wang X, Mahmood K.
    J Bronchology Interv Pulmonol; 2019 Apr 01; 26(2):96-101. PubMed ID: 30048416
    [Abstract] [Full Text] [Related]

  • 25. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
    Arrieta O, Ramírez-Tirado LA, Caballé-Perez E, Mejia-Perez A, Zatarain-Barrón ZL, Cardona AF, Lozano-Ruíz F, Segura-González M, Cruz-Rico G, Maldonado F, Rosell R.
    Thorac Cancer; 2020 Apr 01; 11(4):1026-1037. PubMed ID: 32072746
    [Abstract] [Full Text] [Related]

  • 26. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
    Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H, Ren-Heidenreich L, Shi B, Ren H, Chu X, Kang J, Wang W, Xu J, Tang K, Yang H, Zheng Y, He J, Yu G, Liang N.
    Br J Cancer; 2014 May 27; 110(11):2812-20. PubMed ID: 24743704
    [Abstract] [Full Text] [Related]

  • 27. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, Bae MK, Ou SH, Wang J, Jewell SS, Kang DR, Soo RA, Haack H, Kim JH, Shim HS, Cho BC.
    Ann Oncol; 2013 Sep 27; 24(9):2364-70. PubMed ID: 23788756
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
    Ta TV, Nguyen QN, Chu HH, Truong VL, Vuong LD.
    Pathol Res Pract; 2020 Apr 27; 216(4):152898. PubMed ID: 32089414
    [Abstract] [Full Text] [Related]

  • 31. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ, Haslam A, Gill J, Prasad V.
    Cancer Med; 2022 Sep 27; 11(18):3417-3424. PubMed ID: 35315222
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
    Colombino M, Paliogiannis P, Cossu A, Santeufemia DA, Sardinian Lung Cancer (SLC) Study Group, Sini MC, Casula M, Palomba G, Manca A, Pisano M, Doneddu V, Palmieri G.
    BMC Pulm Med; 2019 Nov 11; 19(1):209. PubMed ID: 31711449
    [Abstract] [Full Text] [Related]

  • 37. ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
    Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H.
    Lung Cancer; 2014 May 11; 84(2):121-6. PubMed ID: 24629636
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.
    Villaruz LC, Socinski MA, Abberbock S, Berry LD, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Varella-Garcia M, Franklin WA, Camidge DR, Sequist LV, Haura EB, Ladanyi M, Kurland BF, Kugler K, Minna JD, Bunn PA, Kris MG.
    Cancer; 2015 Feb 01; 121(3):448-56. PubMed ID: 25273224
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.